Discover
Avigan (favipiravir) / Fujifilm HoldingsJapan’s Avigan stockpile for some 2 million people; No plan for increase: Govt (Pharma Japan) - Mar 18, 2020 - "The Japanese government on March 17 confirmed that it holds enough of Avigan (favipiravir) in stockpile for roughly 2 million people on the basis of its use for new strains of influenza, and there is no plan at this time…"remdesivir (GS-5734) / GileadCoronavirus drugs: Who's doing what, and when they might come (Daily Nation) - Mar 18, 2020 - "Gilead's remdesivir could be the closest to market launch....NIH's Anthony Fauci...overseeing the coronavirus response, has said it could be available in the next 'several months'....'There's only one drug right now that we think may have real efficacy. And that's remdesivir,' said Bruce Aylward, a World Health Organization official at a recent press conference in China....The vaccine began its first human trial....If all goes to plan, it could be available on the market in about a year and a half, ready in case the coronavirus outbreak continues until the next flu season, according to Fauci."Coronavirus Vaccine / CanSinoPICTHA: Phase I Clinical Trial in Healthy Adult (clinicaltrials.gov) - Mar 18, 2020 - P1; N=108; Not yet recruiting; Sponsor: CanSino Biologics Inc.Synairgen to start trial of SNG001 in COVID-19 imminently (GlobeNewswire, Synairgen plc) - Mar 18, 2020 - "Synairgen plc...today announces that it has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients to potentially assist with the global outbreak of the virus."Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19 (GlobeNewswire, Mateon Therapeutics) - Mar 18, 2020 - "Mateon has made significant progress in deploying its phase 3 clinical asset, OT-101, against coronavirus. In an in vitro antiviral testing performed by an independent laboratory, OT-101 has an 50% effective concentration (EC50) of 7.6 µg/mL and is not toxic at the highest dose of 1000 µg/mL giving a safety index (SI) value of >130, which is considered highly active. Mateon intends to work with the Food and Drug Administration (FDA) to permit OT-101 to enter into clinical testing against COVID-19 as soon as preclinical testing is completed."Ergomed announces provision of clinical research services for COVID-19 clinical study (GlobeNewswire, Ergomed plc) - Mar 18, 2020 - "Ergomed plc...today announces the initiation of a study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). EUSA Pharma and the Papa Giovanni XXIII Hospital, Bergamo, Italy announce initiation of an observational case-control study of siltuximab in patients with COVID-19 who have developed serious respiratory complications."Coronavirus Vaccine / GeoVax, BravoVaxGeoVax progresses in coronavirus (COVID-19) vaccine development program (GlobeNewswire) - Mar 18, 2020 - "GeoVax Labs, Inc....provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China."Coronavirus Vaccine / GeoVax, BravoVaxGeoVax progresses in coronavirus (COVID-19) vaccine development program (GlobeNewswire) - Mar 18, 2020 - "GeoVax Labs, Inc....provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China."VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE (GlobeNewswire, Vaxart, Inc.) - Mar 18, 2020 - "SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that it has entered into an agreement with Emergent BioSolutions Inc (NYSE: EBS), whereby Emergent will deploy its molecule-to-market contract development and manufacturing (CDMO) services to help develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.. “I’m pleased that we are joining forces with an experienced manufacturer such as Emergent to help advance our oral COVID-19 vaccine to the clinic,” said Wouter Latour, MD, chief executive officer of Vaxart. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a..."
